On Friday, Xilio Therapeutics Inc (NASDAQ: XLO) opened higher 11.01% from the last session, before settling in for the closing price of $0.96. Price fluctuations for XLO have ranged from $0.62 to $1.70 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 44.05% at the time writing. With a float of $16.42 million, this company’s outstanding shares have now reached $51.78 million.
Let’s look at the performance matrix of the company that is accounted for 64 employees. In terms of profitability, gross margin is 58.82%, operating margin of -613.72%, and the pretax margin is -442.51%.
Xilio Therapeutics Inc (XLO) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Xilio Therapeutics Inc is 68.30%, while institutional ownership is 8.39%. The most recent insider transaction that took place on Jan 02 ’25, was worth 6,841. In this transaction Chief Financial Officer of this company sold 6,954 shares at a rate of $0.98, taking the stock ownership to the 12,421 shares. Before that another transaction happened on Jan 02 ’25, when Company’s SVP, FINANCE AND ACCOUNTING sold 1,803 for $0.98, making the entire transaction worth $1,774. This insider now owns 3,197 shares in total.
Xilio Therapeutics Inc (XLO) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 44.05% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -4.53% during the next five years compared to -11.55% drop over the previous five years of trading.
Xilio Therapeutics Inc (NASDAQ: XLO) Trading Performance Indicators
Check out the current performance indicators for Xilio Therapeutics Inc (XLO). In the past quarter, the stock posted a quick ratio of 1.96. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.98. Likewise, its price to free cash flow for the trailing twelve months is 2.63.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.84, a number that is poised to hit -0.10 in the next quarter and is forecasted to reach -0.80 in one year’s time.
Technical Analysis of Xilio Therapeutics Inc (XLO)
Xilio Therapeutics Inc (NASDAQ: XLO) saw its 5-day average volume 0.76 million, a negative change from its year-to-date volume of 2.93 million. As of the previous 9 days, the stock’s Stochastic %D was 88.43%. Additionally, its Average True Range was 0.09.
During the past 100 days, Xilio Therapeutics Inc’s (XLO) raw stochastic average was set at 41.67%, which indicates a significant decrease from 77.20% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 239.95% in the past 14 days, which was higher than the 184.28% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.7843, while its 200-day Moving Average is $0.8888. Nevertheless, the first resistance level for the watch stands at $1.1533 in the near term. At $1.2367, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.3233. If the price goes on to break the first support level at $0.9833, it is likely to go to the next support level at $0.8967. The third support level lies at $0.8133 if the price breaches the second support level.
Xilio Therapeutics Inc (NASDAQ: XLO) Key Stats
There are currently 51,782K shares outstanding in the company with a market cap of 55.41 million. Presently, the company’s annual sales total 6,340 K according to its annual income of -58,240 K. Last quarter, the company’s sales amounted to 2,930 K and its income totaled -13,270 K.
